BioNTech SE (NASDAQ:BNTX) Shares Sold by Capital International Inc. CA

Capital International Inc. CA reduced its position in shares of BioNTech SE (NASDAQ:BNTX) by 28.2% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 668,315 shares of the company’s stock after selling 262,159 shares during the quarter. BioNTech comprises 0.9% of Capital International Inc. CA’s portfolio, making the stock its 26th largest holding. Capital International Inc. CA owned about 0.28% of BioNTech worth $76,154,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of BNTX. FMR LLC boosted its stake in BioNTech by 22.2% during the fourth quarter. FMR LLC now owns 7,701,476 shares of the company’s stock valued at $877,583,000 after buying an additional 1,401,547 shares in the last quarter. Flossbach Von Storch SE boosted its position in shares of BioNTech by 1.1% during the 4th quarter. Flossbach Von Storch SE now owns 4,406,843 shares of the company’s stock valued at $502,160,000 after purchasing an additional 47,236 shares in the last quarter. Capital International Investors grew its stake in shares of BioNTech by 38.6% in the 4th quarter. Capital International Investors now owns 1,415,566 shares of the company’s stock worth $161,304,000 after purchasing an additional 394,434 shares during the last quarter. abrdn plc raised its holdings in shares of BioNTech by 70.7% in the 4th quarter. abrdn plc now owns 385,668 shares of the company’s stock worth $43,947,000 after purchasing an additional 159,676 shares in the last quarter. Finally, LBP AM SA lifted its stake in BioNTech by 2.1% during the fourth quarter. LBP AM SA now owns 252,918 shares of the company’s stock valued at $28,820,000 after purchasing an additional 5,085 shares during the last quarter. 15.52% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research analysts have issued reports on the stock. Morgan Stanley decreased their price target on shares of BioNTech from $145.00 to $139.00 and set an “overweight” rating on the stock in a research report on Tuesday, March 11th. HC Wainwright decreased their target price on BioNTech from $150.00 to $145.00 and set a “buy” rating on the stock in a report on Tuesday, April 1st. Canaccord Genuity Group reaffirmed a “buy” rating and set a $171.44 target price on shares of BioNTech in a report on Tuesday, March 11th. BMO Capital Markets lifted their price objective on shares of BioNTech from $130.00 to $143.00 and gave the stock an “outperform” rating in a research report on Tuesday, March 11th. Finally, Truist Financial assumed coverage on shares of BioNTech in a research report on Friday, January 10th. They issued a “buy” rating and a $172.00 price target for the company. Three research analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $143.44.

BioNTech Stock Performance

Shares of NASDAQ BNTX opened at $98.76 on Friday. The firm has a market capitalization of $23.70 billion, a price-to-earnings ratio of -47.03 and a beta of 1.07. The company has a current ratio of 7.33, a quick ratio of 7.21 and a debt-to-equity ratio of 0.01. The business has a fifty day simple moving average of $102.79 and a 200 day simple moving average of $111.05. BioNTech SE has a one year low of $76.53 and a one year high of $131.49.

BioNTech (NASDAQ:BNTX) last posted its earnings results on Monday, March 10th. The company reported $1.08 earnings per share for the quarter, beating analysts’ consensus estimates of $0.38 by $0.70. The business had revenue of $1.19 billion for the quarter, compared to analysts’ expectations of $1.24 billion. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. The firm’s revenue for the quarter was down 19.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.90 earnings per share. Sell-side analysts expect that BioNTech SE will post -3.88 EPS for the current year.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.